SCHEMBL417880

SCHEMBL417880

COc1ccc2c(ccn2CCCC(=O)N(C)Cc2cc(F)ccc2OC)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.47
PPARG P37231 4/20 0.45
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
PPARA Q07869 2/20 0.44
TP53 P04637 3/20 0.43
RXFP1 Q9HBX9 2/20 0.43
PPARD Q03181 1/20 0.42
POLB P06746 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
NCOR2 Q9Y618 1/20 0.42
LMNA P02545 1/20 0.42
TSPO P30536 2/20 0.41
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL416248 0.95 NPC1 (0.43) NPC1PPARGPPARATP53RXFP1
SCHEMBL414541 0.90 POLB (0.41) NPC1PPARGPPARATP53POLB
SCHEMBL414591 0.90 NPC1 (0.41) NPC1PPARGPPARATP53RXFP1
SCHEMBL418373 0.90 NPC1 (0.41) NPC1PPARGPPARATP53RXFP1
SCHEMBL417909 0.88 NPC1 (0.39) NPC1PPARGPPARATP53RXFP1
SCHEMBL416574 0.85 TNF (0.39) MTNR1AMTNR1BHTR2AHTR2C
SCHEMBL416672 0.78 NR3C1 (0.42) NPC1RXFP1LMNA
SCHEMBL414508 0.76 GABRP (0.40) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL415868 0.74 NPC1 (0.50) NPC1MTNR1AMTNR1BLMNATSPO
SCHEMBL415358 0.74 PLA2G7 (0.42) HDAC3HDAC1HDAC6TSPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US disclosed
EP-2376431-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2011-10-19 EP disclosed
WO-2010066847-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS CELLVIR (FR) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS HAVCR2, MAVS, EIF2AK2 NPC1 76/4885PPARG 2083/4885MTNR1A 3900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.